The future of smoking cessation therapy in the United States

Authors

  • JOHN R. HUGHES

    Corresponding author
    1. Human Behavioral Pharmacology Laboratory, University of Vermont, USA
      John R. Hughes, MD, University of Vermont, Department of Psychiatry, 38 Fletcher Place, Burlington, VT 05401-1419, USA. Tel: 802-660-3060; Fax: 802-660-3064; e-mail: john.hughes@uvm.edu
    Search for more papers by this author

John R. Hughes, MD, University of Vermont, Department of Psychiatry, 38 Fletcher Place, Burlington, VT 05401-1419, USA. Tel: 802-660-3060; Fax: 802-660-3064; e-mail: john.hughes@uvm.edu

Abstract

Six trends that are likely to influence the future content, format, delivery and reach of smoking cessation therapy in the United States are discussed: (1) changing characteristics of smokers (e.g. more likely to be poor, have psychiatric co-morbidity and be more nicotine dependent), (2) health care reform demands for cost-effectiveness, (3) development of guidelines/algorithms that recommend stepped-care approaches, (4) continued emphasis on smoking as a form of drug dependence requiring intensive pharmacological and behavior therapy for some smokers, (5) interest in harm-reduction strategies for smokers unable or unwilling to qua (and 6) smoking cessation therapies become reimbursable on par with other drug dependencies.

Ancillary